Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma

Biochim Biophys Acta. 2013 Dec;1833(12):2970-2979. doi: 10.1016/j.bbamcr.2013.08.001. Epub 2013 Aug 13.

Abstract

Zinc-binding protein-89 regulates Bak to facilitate apoptosis in cancer cells. This study examined if zinc-binding protein-89 regulates Bak through an epigenetic mechanism in hepatocellular carcinoma. We first demonstrated that the expression of Bak was reduced but the levels of deoxyribonucleic acid methyltransferase 1 and histone deacetylase 3 were increased in hepatocellular carcinoma cancer tissues compared to the corresponding non-cancer tissues. Moreover, there was a negative correlation between Bak expression and deoxyribonucleic acid methyltransferase 1 levels in hepatocellular carcinoma. Administration of zinc-binding protein-89 downregulated histone deacetylase 3 expression and suppressed the activities of histone deacetylase and deoxyribonucleic acid methyltransferase, which led to maintenance of histone acetylation status, inhibited the binding of methyl-CpG-binding protein 2 to genomic deoxyribonucleic acid and demethylated CpG islands in the Bak promoter in hepatocellular carcinoma cells. Using the xenograft mouse tumor model, we demonstrated that zinc-binding protein-89 or inhibitors of either epigenetic enzymes could stimulate Bak expression, induce apoptosis, and arrest tumor growth and that the maximal effort was achieved when zinc-binding protein-89 and the enzyme inhibitors were used in combination. Conclusively, zinc-binding protein-89 upregulates the expression of Bak by targeting multiple components of the epigenetic pathway in hepatocellular carcinoma.

Keywords: 5-Aza-dC; 5-aza-2′-deoxycytidine; Bak; ChIP; Co-IP; DNA methyltransferase; DNMT; HCC; HDAC; Hepatocellular carcinoma; MIHA; MeCP2; VPA; ZBP-89; Zebu; chromatin immunoprecipitation; co-immunoprecipitation; hepatocellular carcinoma; histone deacetylase; immortalized non-tumorigenic hepatocyte cell line; methyl-CpG-binding protein 2; sodium valproic acid; zebularine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Animals
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Base Sequence
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • CpG Islands / genetics
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • DNA-Binding Proteins / metabolism*
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Epigenesis, Genetic* / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylases / metabolism
  • Humans
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology
  • Mice
  • Mice, Nude
  • Molecular Sequence Data
  • Promoter Regions, Genetic / genetics
  • Protein Binding / drug effects
  • Transcription Factors / metabolism*
  • Up-Regulation / drug effects
  • Up-Regulation / genetics*
  • Xenograft Model Antitumor Assays
  • bcl-2 Homologous Antagonist-Killer Protein / genetics*
  • bcl-2 Homologous Antagonist-Killer Protein / metabolism

Substances

  • DNA-Binding Proteins
  • Histone Deacetylase Inhibitors
  • Transcription Factors
  • ZNF148 protein, human
  • bcl-2 Homologous Antagonist-Killer Protein
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases
  • Histone Deacetylases
  • histone deacetylase 3